Potential U.S. targeting casts shadow over WuXi AppTec family
Proposed U.S. legislation could ban federal agencies and federally funded institutions from buying devices and services from Chinese biotech companies Key Takeaways: WuXi AppTec, which could be banned from doing…
FAST NEWS: WuXi XDC’s profit surges on growth in ADC market
The latest: WuXi XDC Cayman Inc. (2268.HK) announced Thursday that it expects to report its net profit last year jumped more than 80% from 2022, while its adjusted net profit and…
WuXi Bio prescribes share buyback to relieve revenue pain
The pharma services provider has shocked investors with a steep downward revision of its earnings outlook, slashing its full-year revenue growth forecast to just 10% from an initial 30% and…
FAST NEWS: WuXi XDC kicks off IPO with star cornerstone investors
The latest: WuXi XDC Cayman Inc. (2268.HK), a unit of WuXi Biologics (Cayman) Inc. (2269.HK), formally launched its initial public offering on Tuesday, with plans to raise up to HK$3.68…
WuXi Biologics hatches new baby with ADC drug unit IPO
The drug outsourcing services company is spinning off its WuXi XDC unit, seizing on investor enthusiasm for a new generation of highly targeted ADC drugs Key Takeaways: WuXi XDC has…
Recent Articles
RELATED ARTICLES
-
WuXi Biologics hatches new baby with ADC drug unit IPO
2269.HK
-
WuXi Bio prescribes share buyback to relieve revenue pain
2269.HK
-
FAST NEWS: JPMorgan boosts WuXi AppTec stake
2359.HK 603259.SHG
- CHINA BULLETIN: Local Governments Crushed by Debt
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK
